Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major Hepatectomy
Liver resection treats primary and secondary liver tumors, though clinical applicability is limited by the remnant liver mass and quality. Herein, major hepatic resections were performed in pigs to define changes associated with sufficient and insufficient remnants and improve liver-specific outcome...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/16/3989 |
| _version_ | 1797524429722353664 |
|---|---|
| author | Amelia J. Hessheimer Jordi Vengohechea Lilia Martínez de la Maza Javier Muñoz Marina Vendrell Josep Martí Sanahuja Alba Torroella Farah Adel Al Shwely Francisco Riquelme César Muñoz Rocío García Pilar Taurá Constantino Fondevila |
| author_facet | Amelia J. Hessheimer Jordi Vengohechea Lilia Martínez de la Maza Javier Muñoz Marina Vendrell Josep Martí Sanahuja Alba Torroella Farah Adel Al Shwely Francisco Riquelme César Muñoz Rocío García Pilar Taurá Constantino Fondevila |
| author_sort | Amelia J. Hessheimer |
| collection | DOAJ |
| description | Liver resection treats primary and secondary liver tumors, though clinical applicability is limited by the remnant liver mass and quality. Herein, major hepatic resections were performed in pigs to define changes associated with sufficient and insufficient remnants and improve liver-specific outcomes with somatostatin therapy. Three experimental groups were performed: 75% hepatectomy (75H), 90% hepatectomy (90H), and 90% hepatectomy + somatostatin (90H + SST). Animals were followed for 24 h (N = 6) and 5 d (N = 6). After hepatectomy, portal pressure gradient was higher in 90H versus 75H and 90H + SST (8 (3–13) mmHg vs. 4 (2–6) mmHg and 4 (2–6) mmHg, respectively, <i>p</i> < 0.001). After 24 h, changes were observed in 90H associated with stellate cell activation and collapse of sinusoidal lumen. Collagen chain type 1 alpha 1 mRNA expression was higher, extracellular matrix width less, and percentage of collagen-staining areas greater at 24 h in 90H versus 75H and 90H + SST. After 5 d, remnant liver mass was higher in 75H and 90H + SST versus 90H, and Ki-67 immunostaining was higher in 90H + SST versus 75H and 90H. As well, more TUNEL-staining cells were observed in 90H versus 75H and 90H + SST at 5 d. Perioperative somatostatin modified portal pressure, injury, apoptosis, and stellate cell activation, stemming changes related to hepatic fibrogenesis seen in liver remnants not receiving treatment. |
| first_indexed | 2024-03-10T08:57:16Z |
| format | Article |
| id | doaj.art-317cbb561fae4403bd9871306ec8fb37 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T08:57:16Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-317cbb561fae4403bd9871306ec8fb372023-11-22T07:02:07ZengMDPI AGCancers2072-66942021-08-011316398910.3390/cancers13163989Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major HepatectomyAmelia J. Hessheimer0Jordi Vengohechea1Lilia Martínez de la Maza2Javier Muñoz3Marina Vendrell4Josep Martí Sanahuja5Alba Torroella6Farah Adel Al Shwely7Francisco Riquelme8César Muñoz9Rocío García10Pilar Taurá11Constantino Fondevila12General & Digestive Surgery Service, Hospital Clínic, 08036 Barcelona, SpainCIBERehd, IDIBAPS, University of Barcelona, 08036 Barcelona, SpainGeneral & Digestive Surgery Service, Hospital Clínic, 08036 Barcelona, SpainCIBERehd, IDIBAPS, University of Barcelona, 08036 Barcelona, SpainAnesthesiology, Hospital Clínic, University of Barcelona, 08036 Barcelona, SpainAnesthesiology, Hospital Clínic, University of Barcelona, 08036 Barcelona, SpainGeneral & Digestive Surgery Service, Hospital Clínic, 08036 Barcelona, SpainGeneral & Digestive Surgery Service, Hospital Clínic, 08036 Barcelona, SpainGeneral & Digestive Surgery Service, Hospital Clínic, 08036 Barcelona, SpainGeneral & Digestive Surgery Service, Hospital Clínic, 08036 Barcelona, SpainGeneral & Digestive Surgery Service, Hospital Clínic, 08036 Barcelona, SpainAnesthesiology, Hospital Clínic, University of Barcelona, 08036 Barcelona, SpainGeneral & Digestive Surgery Service, Hospital Clínic, 08036 Barcelona, SpainLiver resection treats primary and secondary liver tumors, though clinical applicability is limited by the remnant liver mass and quality. Herein, major hepatic resections were performed in pigs to define changes associated with sufficient and insufficient remnants and improve liver-specific outcomes with somatostatin therapy. Three experimental groups were performed: 75% hepatectomy (75H), 90% hepatectomy (90H), and 90% hepatectomy + somatostatin (90H + SST). Animals were followed for 24 h (N = 6) and 5 d (N = 6). After hepatectomy, portal pressure gradient was higher in 90H versus 75H and 90H + SST (8 (3–13) mmHg vs. 4 (2–6) mmHg and 4 (2–6) mmHg, respectively, <i>p</i> < 0.001). After 24 h, changes were observed in 90H associated with stellate cell activation and collapse of sinusoidal lumen. Collagen chain type 1 alpha 1 mRNA expression was higher, extracellular matrix width less, and percentage of collagen-staining areas greater at 24 h in 90H versus 75H and 90H + SST. After 5 d, remnant liver mass was higher in 75H and 90H + SST versus 90H, and Ki-67 immunostaining was higher in 90H + SST versus 75H and 90H. As well, more TUNEL-staining cells were observed in 90H versus 75H and 90H + SST at 5 d. Perioperative somatostatin modified portal pressure, injury, apoptosis, and stellate cell activation, stemming changes related to hepatic fibrogenesis seen in liver remnants not receiving treatment.https://www.mdpi.com/2072-6694/13/16/3989pigliver resectionsmall-for-size syndromepost-hepatectomy liver failure |
| spellingShingle | Amelia J. Hessheimer Jordi Vengohechea Lilia Martínez de la Maza Javier Muñoz Marina Vendrell Josep Martí Sanahuja Alba Torroella Farah Adel Al Shwely Francisco Riquelme César Muñoz Rocío García Pilar Taurá Constantino Fondevila Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major Hepatectomy Cancers pig liver resection small-for-size syndrome post-hepatectomy liver failure |
| title | Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major Hepatectomy |
| title_full | Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major Hepatectomy |
| title_fullStr | Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major Hepatectomy |
| title_full_unstemmed | Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major Hepatectomy |
| title_short | Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major Hepatectomy |
| title_sort | somatostatin therapy improves stellate cell activation and early fibrogenesis in a preclinical model of extended major hepatectomy |
| topic | pig liver resection small-for-size syndrome post-hepatectomy liver failure |
| url | https://www.mdpi.com/2072-6694/13/16/3989 |
| work_keys_str_mv | AT ameliajhessheimer somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT jordivengohechea somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT liliamartinezdelamaza somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT javiermunoz somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT marinavendrell somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT josepmartisanahuja somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT albatorroella somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT farahadelalshwely somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT franciscoriquelme somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT cesarmunoz somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT rociogarcia somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT pilartaura somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy AT constantinofondevila somatostatintherapyimprovesstellatecellactivationandearlyfibrogenesisinapreclinicalmodelofextendedmajorhepatectomy |